PCSK9 Articles

Articles
Safety and Efficacy of PCSK9 Inhibitors in Patients with Acute Coronary Syndrome Who Underwent Coronary Artery Bypass Grafts: A Comparative Retrospective Analysis
Nasso G, Larosa C, Bartolomucci F, et al.
Journal:
J Clin Med

First published: February 4, 2024 DOI: 10.3390/jcm13030907
View
- Share
Articles
The year in cardiovascular medicine 2023: the top 10 papers in dyslipidaemias
Tokgözoğlu L, Orringer C, Catapano AL
Journal:
Eur Heart J

First published: December 28, 2023 DOI: 10.1093/eurheartj/ehad837
View
- Share
Articles
Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials
Wright RS, Koenig W, Landmesser U, et al.
Journal:
J Am Coll Cardiol

First published: December 12, 2023 DOI: 10.1016/j.jacc.2023.10.007
View
- Share
Articles
Ups and downs in PCSK9 inhibition in the cardiovascular arena: a review
McClintick DJ, Giugliano RP
Journal:
Curr Opin Lipidol

First published: December 1, 2023 DOI: 10.1097/MOL.0000000000000897
View
- Share
Articles
Effectiveness and safety of injectable PCSK9 inhibitors in dyslipidaemias’ treatment and cardiovascular disease prevention: An overview of 86 systematic reviews and a network meta-analysis
Pamporis K, Karakasis P, Simantiris S, et al.
Journal:
Clin Investig Arterioscler

First published: November 30, 2023 DOI: 10.1016/j.arteri.2023.11.003
View
- Share
Articles
Bempedoic acid – how will it shape the future lipid-lowering landscape? Mode of action, evidence, and clinical use
Drexel H, Mader A
Journal:
Cardiology

First published: November 21, 2023 DOI: 10.1159/000535372
View
- Share
Articles
Oral strategies to target proprotein convertase subtilisin/kexin type 9 and lipoprotein(a): the new frontier of lipid lowering
Norata GD, Tokgözoğlu L
Journal:
Eur Heart J

First published: November 8, 2023 DOI: 10.1093/eurheartj/ehad682
View
- Share
Articles
First clinical experiences with inclisiran in a real-world setting
Mulder JWCM, Galema-Boers AMH, Roeters van Lennep JE
Journal:
J Clin Lipidol

First published: September 18, 2023 DOI: 10.1016/j.jacl.2023.09.005
View
- Share
Articles
Efficacy and safety of the oral PCSK9 inhibitor MK-0616: a phase 2b randomized controlled trial
Ballantyne CM, Banka P, Mendez G, et al.
Journal:
J Am Coll Cardiol

First published: March 6, 2023 DOI: 10.1016/j.jacc.2023.02.018
View
- Share
Articles
Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial
Schwartz GG, Szarek M, Bhatt DL, et al.
Journal:
Eur Heart J

First published: March 5, 2023 DOI: 10.1093/eurheartj/ehad144
View
- Share
Articles
Addressing current challenges in optimization of lipid management following an ACS event: Outcomes of the ACS EuroPath III initiative
Catapano AL, De Caterina R, Jukema JW, et al.
Journal:
Clin Cardiol

First published: February 17, 2023 DOI: 10.1002/clc.23988
View
- Share
Articles
Association of Rare Protein-Truncating DNA Variants in APOB or PCSK9 With Low-density Lipoprotein Cholesterol Level and Risk of Coronary Heart Disease
Dron JS, Patel AP, Zhang Y, et al.
Journal:
JAMA Cardiol

First published: February 1, 2023 DOI: 10.1001/jamacardio.2022.5271
View
- Share

1 2 3

PCSK9 Articles

Articles

Safety and Efficacy of PCSK9 Inhibitors in Patients with Acute Coronary Syndrome Who Underwent Coronary Artery Bypass Grafts: A Comparative Retrospective Analysis

Nasso G, Larosa C, Bartolomucci F, et al.

Articles

The year in cardiovascular medicine 2023: the top 10 papers in dyslipidaemias

Tokgözoğlu L, Orringer C, Catapano AL

Articles

Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials

Wright RS, Koenig W, Landmesser U, et al.

Articles

Ups and downs in PCSK9 inhibition in the cardiovascular arena: a review

McClintick DJ, Giugliano RP

Articles

Effectiveness and safety of injectable PCSK9 inhibitors in dyslipidaemias’ treatment and cardiovascular disease prevention: An overview of 86 systematic reviews and a network meta-analysis

Pamporis K, Karakasis P, Simantiris S, et al.

Articles

Bempedoic acid – how will it shape the future lipid-lowering landscape? Mode of action, evidence, and clinical use

Drexel H, Mader A

Articles

Oral strategies to target proprotein convertase subtilisin/kexin type 9 and lipoprotein(a): the new frontier of lipid lowering

Norata GD, Tokgözoğlu L

Articles

First clinical experiences with inclisiran in a real-world setting

Mulder JWCM, Galema-Boers AMH, Roeters van Lennep JE

Articles

Efficacy and safety of the oral PCSK9 inhibitor MK-0616: a phase 2b randomized controlled trial

Ballantyne CM, Banka P, Mendez G, et al.

Articles

Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial

Schwartz GG, Szarek M, Bhatt DL, et al.

Articles

Addressing current challenges in optimization of lipid management following an ACS event: Outcomes of the ACS EuroPath III initiative

Catapano AL, De Caterina R, Jukema JW, et al.

Articles

Association of Rare Protein-Truncating DNA Variants in APOB or PCSK9 With Low-density Lipoprotein Cholesterol Level and Risk of Coronary Heart Disease

Dron JS, Patel AP, Zhang Y, et al.

Articles

Safety and Efficacy of PCSK9 Inhibitors in Patients with Acute Coronary Syndrome Who Underwent Coronary Artery Bypass Grafts: A Comparative Retrospective Analysis

Nasso G, Larosa C, Bartolomucci F, et al.

Share

Articles

The year in cardiovascular medicine 2023: the top 10 papers in dyslipidaemias

Tokgözoğlu L, Orringer C, Catapano AL

Share

Articles

Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials

Wright RS, Koenig W, Landmesser U, et al.

Share

Articles

Ups and downs in PCSK9 inhibition in the cardiovascular arena: a review

McClintick DJ, Giugliano RP

Share

Articles

Effectiveness and safety of injectable PCSK9 inhibitors in dyslipidaemias’ treatment and cardiovascular disease prevention: An overview of 86 systematic reviews and a network meta-analysis

Pamporis K, Karakasis P, Simantiris S, et al.

Share

Articles

Bempedoic acid – how will it shape the future lipid-lowering landscape? Mode of action, evidence, and clinical use

Drexel H, Mader A

Share

Articles

Oral strategies to target proprotein convertase subtilisin/kexin type 9 and lipoprotein(a): the new frontier of lipid lowering

Norata GD, Tokgözoğlu L

Share

Articles

First clinical experiences with inclisiran in a real-world setting

Mulder JWCM, Galema-Boers AMH, Roeters van Lennep JE

Share

Articles

Efficacy and safety of the oral PCSK9 inhibitor MK-0616: a phase 2b randomized controlled trial

Ballantyne CM, Banka P, Mendez G, et al.

Share

Articles

Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial

Schwartz GG, Szarek M, Bhatt DL, et al.

Share

Articles

Addressing current challenges in optimization of lipid management following an ACS event: Outcomes of the ACS EuroPath III initiative

Catapano AL, De Caterina R, Jukema JW, et al.

Share

Articles

Association of Rare Protein-Truncating DNA Variants in APOB or PCSK9 With Low-density Lipoprotein Cholesterol Level and Risk of Coronary Heart Disease

Dron JS, Patel AP, Zhang Y, et al.

Share